SOM Biotech is one of the finalist companies of the Entrepreneur XXI prize among more than 600 participants. Prize granted by “La Caixa” and ENISA. ( http://premios2013.emprendedorxxi.es/) (Winners 2013)
SOM Biotech, has been identified as one of the best opportunities to invest in start-up biopharmaceuticals companies in Catalonia. Link: http://www.neweuropeaneconomy.com/home-mainmenu-51/fdi-mainmenu-59/514-adding-value-to-existing-drugs
A recent Thomson Reuters report indicates that drug repositioning is expected to generate up to $20Billion in annual sales during 2012, thus opening up a new source of revenue to large, medium and small Pharma companies.
SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIIIth International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.
SOM Biotech has been granted SME status as micro-sized enterprise in research and development by the European Medicine Agency (EMA). The main incentives include: fee reductions in regulatory procedures and scientific advice, administrative assistance, and more economical access to various services provided by EMA.
SOM Biotech will attend BioBusiness 2012 that will take place from 31 January to 2 February 2012 in London. BioBusiness is the leading high-level BioPharma strategy and bio-partnering conference.
SOM Biotech will present the company to private investors during the Biotech Showcase™ and J.P. Morgan Healthcare Conference that will take place from 9th to 12th January 2012 in San Francisco, CA.